A research collaboration has been signed between Embark Biotech and Novo Nordisk to discover novel treatments for obesity and its associated metabolic pathologies. Embark Biotech is a recent spin-out from the Center for Basic Metabolic Research at University of Copenhagen; its technological platform focuses on receptors that stimulate energy expenditure without triggering the sympathetic nervous system (the ‘fight-or-flight’ response). The aim of the collaboration is to develop novel drug candidates that help people with obesity lose weight by burning off excess energy instead of storing it as fat.

LEAVE A REPLY

Please enter your comment!
Please enter your name here